FMP

FMP

Enter

MNKD - MannKind Corporation

Profile of MannKind Corporation(MNKD), MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization

About

ceo

Dr. Michael E. Castagna Pharm.D.

sector

Healthcare

industry

Biotechnology

website

https://www.mannkindcorp.com

exchange

NASDAQ

Description

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.

CIK

0000899460

ISIN

US56400P7069

CUSIP

56400P706

Address

30930 Russell Ranch Road

Phone

818 661 5000

Country

US

Employee

411

IPO Date

Jul 28, 2004

Key Executives

page loading card
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep